Muri, Jonathan Cecchinato, Valentina Cavalli, Andrea Shanbhag, Akanksha A. Matkovic, Milos Biggiogero, Maira Maida, Pier Andrea Moritz, Jacques Toscano, Chiara Ghovehoud, Elaheh Furlan, Raffaello Barbic, Franca Voza, Antonio De Nadai, Guendalina Cervia, Carlo Zurbuchen, Yves Taeschler, Patrick Murray, Lilly A. Danelon-Sargenti, Gabriela Moro, Simone Gong, Tao Piffaretti, Pietro Bianchini, Filippo Crivelli, Virginia Podešvová, Lucie Pedotti, Mattia Jarrossay, David Sgrignani, Jacopo Thelen, Sylvia Uhr, Mario Bernasconi, Enos Rauch, Andri Manzo, Antonio Ciurea, Adrian Rocchi, Marco B. L. Varani, Luca Moser, Bernhard Bottazzi, Barbara Thelen, Marcus Fallon, Brian A. Boyman, Onur Mantovani, Alberto Garzoni, Christian Franzetti-Pellanda, Alessandra Uguccioni, Mariagrazia Robbiani, Davide F 2023 Infection with severe acute respiratory syndrome coronavirus 2 associates with diverse symptoms, which can persist for months. While antiviral antibodies are protective, those targeting interferons and other immune factors are associated with adverse coronavirus disease 2019 (COVID-19) outcomes. Here we discovered that antibodies against specific chemokines were omnipresent post-COVID-19, were associated with favorable disease outcome and negatively correlated with the development of long COVID at 1 yr post-infection. Chemokine antibodies were also present in HIV-1 infection and autoimmune disorders, but they targeted different chemokines compared with COVID-19. Monoclonal antibodies derived from COVID-19 convalescents that bound to the chemokine N-loop impaired cell migration. Given the role of chemokines in orchestrating immune cell trafficking, naturally arising chemokine antibodies may modulate the inflammatory response and thus bear therapeutic potential. application/pdf https://n2t.net/ark:/12658/srd1330479 https://susi.usi.ch/global/documents/330479 https://susi.usi.ch/documents/330479/files/Robbiani_2023_Nature_Nat Immunology.pdf eng info:eu-repo/semantics/altIdentifier/doi/10.1038/s41590-023-01445-w info:eu-repo/semantics/altIdentifier/ark/12658/srd1330479 info:eu-repo/semantics/openAccess CC BY Nature immunology. - 2023, vol. 24, p. 604-611 info:eu-repo/classification/udc/61 Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course http://purl.org/coar/resource_type/c_6501